HUTCHMED (China)CHIX:HCML 60 10-Year ROIIC % is -8.31 as of Dec. 2025. GuruFocus rates CHIX:HCML with a GF Score™ of 60/100 and a GF Value™ of £2.24 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 860 Drug Manufacturers companies, HUTCHMED (China) ranks worse than 76.16% on this metric.
10-Year Return on Invested Incremental Capital (10-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 10-year.
HUTCHMED (China)'s 10-Year ROIIC % for the quarter that ended in Dec. 2025 was -8.31%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for HUTCHMED (China)'s 10-Year ROIIC % or its related term are showing as below:
CHIX:HCMl's 10-Year ROIIC % is ranked worse than 76.16% of 860
companies
in the Drug Manufacturers industry
Industry Median: 4.41
vs CHIX:HCMl: -8.31
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
HUTCHMED (China) 10-Year ROIIC % Related Terms
HUTCHMED (China) 10-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for HUTCHMED (China)'s 10-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:HCML vs ZTS, UTHR, VTRS: 10-Year ROIIC % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, HUTCHMED (China)'s 10-Year ROIIC %, along with its competitors' market caps and 10-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HUTCHMED (China) 10-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, HUTCHMED (China)'s 10-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where HUTCHMED (China)'s 10-Year ROIIC % falls into.
HUTCHMED (China)'s 10-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
10-Year ROIIC %
=
10-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
10-Year Incremental Invested Capital**
=
( -23.2651632 (Dec. 2025) - -6.527 (Dec. 2015) )
/
( 326.595 (Dec. 2025) - 125.251 (Dec. 2015) )
=
-16.7381632
/
201.344
=
-8.31%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 10-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
HUTCHMED (China) (CHIX:HCML) has a 10-Year ROIIC % of -8.31 as of Dec. 2025. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on HUTCHMED (China) and its competitors. According to the industry distribution chart, HUTCHMED (China) ranks #655 out of 860 companies in the Drug Manufacturers industry, placing it in the top 76.2%.
Is HUTCHMED (China)'s 10-Year ROIIC % too high?
HUTCHMED (China)'s current 10-Year ROIIC % is -8.31. Based on the distribution chart, HUTCHMED (China) ranks #655 out of 860 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, HUTCHMED (China) has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does HUTCHMED (China)'s 10-Year ROIIC % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, HUTCHMED (China) ranks #655 out of 860 companies for 10-Year ROIIC %. This places HUTCHMED (China) in the lower half of its industry. The industry median 10-Year ROIIC % is 4.41. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year ROIIC % for a Drug Manufacturers company?
The median 10-Year ROIIC % among Drug Manufacturers companies is 4.41, based on 860 companies in the industry. Companies in the top quartile (top 25%) have a 10-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 10-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year ROIIC % mean?
A high 10-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on HUTCHMED (China) and its competitors. For the Drug Manufacturers industry, the median 10-Year ROIIC % is 4.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HUTCHMED (China)'s current 10-Year ROIIC % is -8.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HUTCHMED (China) stock overvalued right now?
Based on GuruFocus' analysis, HUTCHMED (China) (CHIX:HCML) is currently considered Modestly Undervalued. The stock's GF Value™ is £2.24, compared to a current price of £1.67 — trading 25.4% below its estimated fair value. The current 10-Year ROIIC % is -8.31. HUTCHMED (China)'s overall GF Score™ is 60/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year ROIIC % calculated?
10-Year ROIIC % is calculated from a company's financial statements. For HUTCHMED (China) (CHIX:HCML), the current 10-Year ROIIC % is -8.31 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HUTCHMED (China) (CHIX:HCML) Overvalued in 2026?
Based on GuruFocus' analysis, HUTCHMED (China) stock appears to be undervalued.
The current stock price of £1.67 is trading 25.4% below its estimated GF Value™ of £2.24.
GuruFocus considers HUTCHMED (China) to be Modestly Undervalued.
Key valuation signals for CHIX:HCML:
10-Year ROIIC %: -8.31
GF Value™: £2.24 vs. price of £1.67 (25.4% below fair value)
No single metric tells the full story. See the CHIX:HCML stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.
60GF Score
Get the complete analysis for CHIX:HCML
10-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:HCML has been successfully added to your 
